Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Abcam Plc LSE:ABC London Ordinary Share GB00B6774699 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -9.00 -0.66% 1,359.00 1,358.00 1,360.00 1,390.00 1,356.00 1,390.00 489,741 16:15:58
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 260.0 8.4 6.0 226.5 3,082

Abcam Share Discussion Threads

Showing 1026 to 1047 of 1050 messages
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
DateSubjectAuthorDiscuss
07/6/2021
19:04
Personally I think you are looking at noise. I'm not remotely worried by it but I'll leave you to it if you want to look at tea leaves moving around your cup. I'd go mental if i took note of every move like that in my Portfolio
davr0s
07/6/2021
11:40
It won't look as dramatic on a 1 or 3 year chart. But it would on a weekly chart comparing TY & LY for example.
lord loads of lolly
07/6/2021
05:51
I tend to disagree - if I look at a 1 or 3 year chart last week doesn't stick out to me. Don't think there is anything to see here
davr0s
06/6/2021
23:26
But if you look at historical share price movement, it’s been a lot less volatile than last week’s.
lord loads of lolly
06/6/2021
15:08
Yeah it's a pharma stock which attracts this kind of volatility
davr0s
03/6/2021
10:48
Abnormal share price volatility here currently. First a 48p (3.39%) drop on 1 June. Then a 56p (4.12%) rise earlier today (3 June) - though most of it evaporated by the close. Can't see anything in June's RNSs to explain it either. Bizarre! Ideas anyone?
lord loads of lolly
01/6/2021
17:08
bulltradept - Sept 20 means this review is old news. It also comes from Chronic Investors, who've a very mixed stock picking track record. On a separate issue, anyone care to hazard a guess what prompted today's 48p (3.39%) drop?
lord loads of lolly
01/6/2021
16:09
The IC has it as a hold Abcam hampered by research shut-downs However, the group has maintained its longer-term targets, while putting the dividend on ice September 14, 2020 By Harriet Clarfelt Antibodies have been a much-discussed topic since the outbreak of Covid-19, playing a central role in testing and treatment programmes. These blood proteins, which develop in response to infection, can show whether a person has already had a disease – helping authorities to monitor the spread of infection. Scientists are also investigating whether antibody therapy can aid patients who are still sick. IC TIP: Hold at 1366p ABC:LSE Abcam PLC 1mth Today change -3.04%Price (GBP) 1,373.00 But the buzz around antibodies and coronavirus forms just one part of a vast global research landscape. And aside from work to target the pandemic, most laboratories were shuttered when lockdowns took hold. Thus, while Abcam (ABC) saw some benefit from the use of its products in virus studies during the 12 months to June, this was tempered by reduced demand elsewhere. The group – which makes and sells protein-research tools, including antibodies, to the life sciences sector – reported revenues of £260m; flat year-on-year, or down 1.4 per cent at constant currencies. Abcam explained that timings “correlated strongly” with the phasing of global government shutdowns. While the first half of the year saw 10.8 per cent sales growth, the second half saw a proportionate decline. However, on a more positive note, the group has not observed any big changes to its underlying customer base. What’s more, management observed that by June 2020, demand was roughly in line with levels seen the previous summer. That recovery goes some way to explain the group’s reiteration of its 2023/24 targets and its associated investment plans. Bosses are aiming for revenues of £450-500m, an adjusted operating margin of more than 30 per cent and a return on capital employed (ROCE) of over 18 per cent. The effects of such an expenditure strategy were evident at the interim mark. When combined with the blow dealt by Covid-19, adjusted costs rose by more than a third to £136m – higher than Peel Hunt’s estimate of £111m. In turn, adjusted operating profits halved to £44.5m, on a margin of 17.1 per cent – down from 32.2 per cent. The broker noted that the “small miss” on costs may have read-across for anticipated expenses in FY2021. The statutory story was rather more dramatic, with pre-tax profits plunging by 85 per cent to £8.4m. This reflected a number of dampeners – the largest of which was the £14.9m write-down of certain technologies tied to Abcam’s acquisition of AxioMx five years ago. Abcam noted that while this is proving commercial feasibility, it has yet to see usage at a scale to support its asset value. Other factors at play included system improvement costs, and spending on the purchase of Expedeon’s proteomics (protein study) and immunology businesses. Meanwhile, in a bid to boost its flexibility around capital allocation, Abcam has put the dividend on ice, with a view to injecting more money into growth opportunities. At the same time, and in the same vein, the group is moving forward with plans to pursue a secondary listing on America’s Nasdaq index. Little wonder, perhaps; more than two-fifths of revenues stem from the US. The improving trends towards the end of Abcam’s fiscal year have continued into the current period, with more labs reopening - and the maintenance of its longer-term growth ambitions is encouraging. Chief executive Alan Hirzel also noted that Covid-19’s broad impact on the immune response has meant that “all kinds of new questions [are] being raised about immunology”. Abcam has accelerated its investments in this research area, “knowing that Covid is likely to spark long-term interest in that field”. Still, for now the crisis continues, and it is impossible to know whether restrictions will be reintroduced – meaning that the group has not offered up full-year guidance. A forward price/earnings multiple of more than 70 times (based on Numis’s projections) keeps us neutral. Last IC view: Hold, 1,143p, 09 Mar 2020
bulltradept
19/5/2021
16:13
Looks to be good support at 1400p, otherwise 1200p! Exasperating share however.
mayers
31/3/2021
20:26
Could we be having a very promising day tomorrow, I wonder!
reb_ban
30/3/2021
17:15
Completely manipulated but I doubt its long for some positive momentum in price here...
reb_ban
30/3/2021
16:45
Well,it always looked as if it was going to fall to 1400 and it is to be hoped that the former support level holds. I imagine the chartists would see this as a head and shoulders development. Strange share particularly at a time where biochemistry techniques are so much to the fore.
mayers
29/3/2021
13:26
Well I'm keen considering technicals are becoming quite interesting now...
reb_ban
09/3/2021
10:37
Been in and out of this for years: well managed company but numbers this year have been ordinary. Not sure why they didn't benefit from CV-19. They will be back up again; Nasdaq listing helped a lot. Under 1500 is surely a good [re-] entry point.
don carter
08/3/2021
10:50
I don't know, unless something has leaked from the results due at 12.00. I've been waiting for an entry point here and bought for the first time yesterday and more this morning, so fingers X-ed it ain't a falling knife.
jeffian
08/3/2021
09:18
Why the sell off? Have I missed something?
ifthecapfits
12/1/2021
18:39
Very good day. Nice results too.
ifthecapfits
04/1/2021
13:03
Quiet board. But progressing nicely.
ifthecapfits
05/10/2020
11:47
Proposed US listing could impact ABC's Inheritance Tax qualifying status of the AIM shares. Investor's Champion's updated AIMsearch tool, a unique search facility which helps identify Inheritance Tax qualifying AIM companies, will provide further updates on this.
energeticbacker
05/10/2020
08:43
Good question. Don't know.
ifthecapfits
05/10/2020
07:53
Will this US listing affect ABC's AIM IHT status?
slogsweep
24/7/2020
11:09
"You can use our updated AIMsearch tool" Aye, if you pay for it!
jeffian
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
ADVFN Advertorial
Your Recent History
LSE
ABC
Abcam
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210618 15:32:24